Home/Pipeline/SP-2577 (Seclidemstat)

SP-2577 (Seclidemstat)

Sarcomas & Solid Tumors

Phase 1/2ActiveNCT03895684

Key Facts

Indication
Sarcomas & Solid Tumors
Phase
Phase 1/2
Status
Active
Company

About Sumitomo Pharma

Sumitomo Pharma's mission is to translate cutting-edge science into innovative therapies that address significant unmet medical needs, particularly in psychiatry and oncology. The company has achieved global recognition through its commercialized products like Latuda® (lurasidone) and is advancing a robust pipeline of next-generation modalities. Its strategy hinges on a balanced portfolio, combining revenue-generating assets with high-risk, high-reward R&D in gene therapy and radiopharmaceuticals, supported by strategic global partnerships and internal discovery capabilities.

View full company profile